Related Experiment Video

Updated: Oct 11, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K

Glycemic Control in Hospitalized Stroke Patients: A Review

Vishal N Patel1, Emory Kuo2

  • 1Emory University School of Medicine Neuroscience Critical Care, Emory Healthcare Marcus Neuroscience ICU, Grady Memorial Hospital, 49 Jesse Hill Jr Drive SE, Office # 386, Atlanta, GA, 30303, USA. vishal.patel@emory.edu.

Current Diabetes Reports
|December 1, 2021
PubMed
Abstract

Insights

Glycemic control targets for hospitalized stroke patients lack clear guidelines. The SHINE trial found no significant difference between aggressive and standard glycemic control in acute ischemic stroke.

Area of Science:

  • Neurology
  • Endocrinology
  • Clinical Trials

Background:

  • Glycemic control targets in hospitalized stroke patients were previously unclear.
  • The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial investigated glycemic control in acute ischemic stroke.

Purpose of the Study:

  • To review clinical trials on glycemic control in hospitalized stroke patients.
  • To examine oral medications for glycemic control in stroke.
  • To discuss GLP-1 agonists in ischemic stroke research.

Main Methods:

  • Review of clinical trials and oral medications for glycemic control in stroke.
  • Analysis of findings from the SHINE trial.
  • Exploration of emerging research on GLP-1 agonists.

Main Results:

  • The SHINE trial showed no significant difference between aggressive and standard glycemic control in acute ischemic stroke.
  • Glycemic control in non-acute stroke types (SAH, ICH) requires further investigation.
  • The role of non-insulin medications in stroke glycemic control is an area for future research.

Conclusions:

  • Current glycemic control targets for acute ischemic stroke patients lack definitive evidence for aggressive control.
  • Further research is needed for optimal glycemic management in diverse stroke populations and with various medication classes, including GLP-1 agonists.
Keywords:
GLP-1 agonistsGlycemic controlSHINE trialStroke

More Related Videos

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia09:35

A Mouse Model of Hemorrhagic Transformation Induced by Acute Hyperglycemia Combined with Transient Focal Ischemia

Published on: November 15, 2024

593
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.2K

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
378
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
448
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
95
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
48
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
63
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
300